Nicholas Baxter - Jul 25, 2023 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Director
Signature
/Nicholas Baxter/
Stock symbol
LEXX
Transactions as of
Jul 25, 2023
Transactions value $
$0
Form type
4
Date filed
7/25/2023, 02:35 PM
Previous filing
Oct 13, 2022
Next filing
May 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 11K Jul 25, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +5K +16.67% $0.00 35K Jul 25, 2023 Common Shares 5K $0.87 Direct
holding LEXX Stock Options 1.5K Jul 25, 2023 Common Shares 1.5K $3.00 Direct F1
holding LEXX Stock Options 6.5K Jul 25, 2023 Common Shares 5K $3.00 Direct F2
holding LEXX Stock Options 8.4K Jul 25, 2023 Common Shares 1.9K $3.00 Direct F3
holding LEXX Stock Options 11.8K Jul 25, 2023 Common Shares 3.4K $3.39 Direct
holding LEXX Stock Options 30K Jul 25, 2023 Common Shares 18.2K $1.96 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9,2023